top of page



・Sato N, Li W, Tsubaki M, Higai K, Takemoto M, Sasaki T, Onoda T, Suzuki T, Koike K:Flavonoid glycosides from Japanese Camellia oil cakes and their inhibitory activity against advanced glycation end-products formation. Journal of Functional Foods, 35, 159–165, 2017.

・Onoda T, Li W, Sasaki T, Miyake M, Higai K, Koike K:Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan, Journal of Ethnopharmacology 186 ,84–90, 2016. 

・Sasaki T., Li W., Higai K., Koike K.: Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors.Bioorg Med Chem Lett. 1;25(9):1979-1981 2015.

・Nagai H, Mukozu T, Ogino YU, Matsui D, Matsui T, Wakui N, Momiyama K, Igarashi Y, Sumino Y, Higai K: Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. Anticancer Res. 35(4):2269-2277 2015.

・Onoda T., Li W., Higai K, Koike K:Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents. BMC Complement Altern Med. 14:64. 2014. 

・Sasaki T., Li W., Higai K., Quang T., Kim Y.,2, Koike K.: Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens.  Planta Medica  80(07): 557-560 2014. 

・ Taniuchi F., Higai K., Tanaka T., Azuma Y.. Matsumoto K.: Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells. Scientific World Journal 105464 2013. 

・ Li W., Li S., Higai K., Sasaki T., Asada Y., Ohshima S., Koike K.:Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett. 1;23(21):5836-5839 2013. 

・Li D., Li W., Higai K, Koike K.:Protein tyrosine phosphatase 1B inhibitory activities of ursane- and lupane-type triterpenes from Sorbus pohuashanensis. J Nat Med., 68(2):427-431 2013.     

・Ito K., Higai K., Shinoda C., Sakurai M., Yanai K., Azuma Y., Matsumoto K. :Unlike NKp30, natural cytotoxicity receptor NKp44 binds to multimeric a2,3-NeuNAc-containing N-glycans. Biol. Pharm. Bull. 35 (4), 594-600 2012.

Higai K., Matsumoto K.: Glycan ligand specificity of killer lectin receptors. Yakugaku Zasshi. 132(6):705-712 2012.

Higai K., Suzuki C., Imaizumi Y., Xin Xin, Azuma Y. and Matsumoto K: Binding affinities of NKG2D and CD94 to sialyl Lewis X-expressing N-glycans and heparin. Biol. Pharm. Bull. 34(1): 8-12 2011. 

・Xin X, Higai K., Imaizumi Y., Suzuki C.,Ito K., Itoh A., Matsumoto S., Azuma Y.,and Matsumoto K.: NKG2A and NKG2C bind to sulfated glycans and a2,3-NeuAc-containing glycoproteins.  Biol. Pharm. Bull. 34(4):480-485 2011.

・Ito K., Higai K., Sakurai M., Shinoda C., Yanai K., Azuma Y. and Matsumoto K.: Binding of Natural cytotoxicity receptor NKp46 to sulfate- and a2,3-NeuAc-containing glycans and its mutagenesis.  Biochem, Biophys. Res. Commun. 406 (3):377-382 2011.

Higai K., Itoh A., Imaizumi Y., Suzuki C., Xin X., Azuma Y. and Matsumoto K.: Binding properties of CD94 to sulfated glycans and a2,3-NeuAc-containing glycoprotein and its mutagenesis analysis. The Open Biotechnology Journal, 5,14-20 2011.

・ Azuma Y, Nakagawa H, Dote K, Higai K and Matsumoto K: Decreases in CD31 and CD47 levels on the cell surface during etoposide-induced Jurkat cell apoptosis.  Biol. Pharm. Bull.34 (12), 1828-1834 2011. 

Higai K., Matsumoto S.,Kimura M.,Imaizumi Y.,Yanai K., Azuma Y., Matsumoto K.: NKG2D: Binding Properties for Glycan Ligands, and Mutagenesis Analysis. The Open Biotechnology Journal, 5,33-38 2011.

Higai K, Tsukada M., Moriya Y., Azuma Y., and Matsumoto K.: Prolonged culture in high glucose suppresses phorbol 12-myristate 13-acetate and ionomycin-induced interleukin-2 mRNA expression in Jurkat cells via accumulation of inducible cAMP early repressor. Biochim Biophys Acta. 1790 :8-15 2009. 

・ Imaizumi Y., Higai K., Suzuki C, Azuma Y, Matsumoto K.: NKG2D and CD94 bind to multimeric a2,3-linked N-acetylneuraminic acid. Biochem, Biophys. Res. Commun. 382:604-608 2009.

Higai K., Imaizumi Y., Suzuki C, Azuma Y. and Matsumoto K.: NKG2D and CD94 bind to heparin and sulfate-containing polysaccharides. Biochem, Biophys. Res. Commun. 386:709-714 2009.

・Sato H., Azuma Y., Higai K., Matsumoto K.: Altered expression of glycoproteins on the cell surface of Jurkat cells during etoposide-induced apoptosis: Shedding and intracellular translocation of glycoproteins. Biochimica et Biophysica Acta (BBA) - General Subjects, 1790 (10): 1198-1205 2009.

Higai K, Satake M, Nishioka H, Azuma Y and Matsumoto K: Glycated human serum albumin enhances macrophage inflammatory protein-1b mRNA expression through protein kinase C-δ and NADPH oxidase in macrophage-like differentiated U937 cells. Biochim Biophys Acta. 1780 (2):307-314 2008.

Higai K, Miyazaki N, Azuma Y and Matsumoto K: Transcriptional regulation of the fucosyltransferase VI gene in hepatocellular carcinoma cells. Glycoconj. J. (3):225-235 2008.

・Azuma Y, Kurusu Y, Sato H, Higai K, and Matsumoto K: Increased Expression of Lewis X and Y Antigens on the Cell Surface and FUT 4 mRNA during Granzyme B-Induced Jurkat Cell Apoptosis.  Biol. Pharm. Bull. 30(4) :655-660,2007.

・Azuma Y, Sato H, Higai K, and Matsumoto K: Enhanced expression of membrane-associated sialidase Neu3 decreases GD3 and increases GM3 on the surface of Jurkat cells during etoposide-induced apoptosis. Biol. Pharm. Bull. 30(9):1680-1684, 2007.

Higai K, Sano R, Satake M, Azuma Y, and Matsumoto K: Glycated human serum albumin induced Interleukin 8 mRNA expression through reactive oxygen species and NADPH oxidase-dependent pathway in monocyte-derived U937 cells. Biol. Pharm. Bull. 30(10):1833-1837, 2007.

・Azuma Y, Miura K, Higai K, Matsumoto K: Protein O-N-acetylglucosaminylation modulates promoter activities of cyclic AMP response element and activator protein 1 and enhances E-selectin expression in HuH-7 human hepatoma cells. Biol Pharm Bull. 30(12) :2284-2289 2007.

Higai K, Ichikawa A, Matsumoto K: Binding of sialyl Lewis X antigen to lectin-like receptors on NK cells induces cytotoxicity and tyrosine phosphorylation of a 17-kDa protein. Biochim Biophys Acta.1760(9):1355-1363, 2006.

Higai K, Shimamura A, Matsumoto K: Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin. Chim. Acta 367 (1-2) 137-143, 2006.

Higai K, Ishihara S, and Matsumoto K: Nuclear factor kB-p65-dependent transcriptional regulation of fucosyltransferase and sialyltransferase in human colon adenocarcinoma HT-29 cells. Biol. Pharm. Bull. (Highlighted paper selected by Editor-in-chief )12:2372-2377,2006.

Higai K, Miyazaki N, Azuma Y and Matsumoto K: Interleukin-1b induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. FEBS lett., 580(26):6069-6075, 2006.

Higai K, Aoki Y, Matsumoto K: Glycosylation of site-specific glycans of alpha(1)-acid glycoprotein and alterations in acute and chronic inflammation. Biochim Biophys Acta. 1725(1):128-135, 2005.

Higai K, Shibukawa K, Muto S, Matsumoto K:Targeted proteo-glycomics analysis of sialyl Lewis X expressing glycoproteins secreted by HepG2 cells. Anal Sci 19(1):85-92, 2003. 

Higai K, Azuma Y, Aoki Y, Matsumoto K: Altered glycosylation of a1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin Chim Acta 329(1-2):117-125, 2003.

・Taniguchi A, Hasegawa Y, Higai K, Matsumoto K: Transcriptional regulation of human b-galactoside a2,6-sialyltransferase (hST6Gal I) gene during differentiation of the HL-60 cell line. Glycobiology 10(6):623-628, 2000.

・Taniguchi A, Hasegawa Y, Higai K, Matsumoto K: Down-regulation of human Galβ1,3 GalNAc/Galβ1,4GlcNAc α2,3-sialyltransferase (hST3Gal IV) gene during differentiation of the HL-60 cell line.  Mol Cell Biol Res Commun 2(3):197-201, 1999.

Higai K, Masuda D, Matsuzawa Y, Satoh T, Matsumoto K:A fluorometric assay for glycosyltransferase activities using sugars aminated and tagged with 7-hydroxycoumarin-3-carboxylic acid as substrates and high performance liquid chromatography. Biol Pharm Bull 22(4):333-338, 1999. 

・Taniguchi A, Higai K, Hasegawa Y, Utsumi K, Matsumoto K: Differentiation elicits negative regulation of human β-galactoside α2,6-sialyltransferase at the mRNA level in the HL-60 cell line.  FEBS Lett 441(2):191-194, 1998. 

bottom of page